{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:02:03Z","timestamp":1790222523204,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"1","funder":[{"name":"UCF Doctoral Research Support award"},{"name":"Florida Legislative Grant"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2018,12,6]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background\ufeff<\/jats:title>\n                  <jats:p>Monoclonal antibodies inhibiting tumour necrosis factor-\u03b1 (TNF\u03b1) signalling pathway (anti-TNF\u03b1) have been widely used in Crohn\u2019s disease (CD). However, treatment response varies among patients with CD and the clinical outcome is dependent on single nucleotide polymorphisms (SNP) in TNF\u03b1 receptor superfamily 1A and 1B (<jats:italic>TNFRSF1A\/1B<\/jats:italic>).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We tested nine SNPs in <jats:italic>TNF\u03b1, TNFRSF1A<\/jats:italic> and <jats:italic>TNFRSF1B<\/jats:italic> by TaqMan genotyping from peripheral blood samples of 104 subjects. Additionally, we quantified the effects of these SNPs on their corresponding gene expression by RT-PCR and susceptibility to <jats:italic>Mycobacterium avium<\/jats:italic> subsp <jats:italic>paratuberculosis<\/jats:italic> (MAP) infection by <jats:italic>IS900<\/jats:italic> nested PCR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Four SNPs (<jats:italic>TNF\u03b1:rs1800629, TNFRSF1A:rs767455, TNFRSF1B:rs1061624<\/jats:italic> and <jats:italic>TNFRSF1B:rs3397<\/jats:italic>) were over-represented significantly (p&lt;0.05) among patients with CD compared with healthy controls. The <jats:italic>TNFRSF1A:rs767455<\/jats:italic> GG genotype was found in 15\/54\u2009patients with CD (28%), while it was only found in 2\/50 healthy controls (4%) (OR 9.2, 95%\u2009CI 1.98 to 42.83). The <jats:italic>TNFRSF1B:rs3397<\/jats:italic> TT genotype was found in 15\/54\u2009patients with CD (28%) compared with (4\/50) healthy controls (8%) (OR 4.4, 95%\u2009CI 1.36 to 14.14). Furthermore, the SNPs <jats:italic>TNFRSF1A:rs767455<\/jats:italic> and <jats:italic>TNFRSF1B:rs3397<\/jats:italic> were associated with downregulating their corresponding genes significantly (p&lt;0.05). MAP infection was predominantly found among patients with CD in comparison to healthy controls (57% vs 8%, respectively), which was also dependent on the SNPs <jats:italic>TNFRSF1A:rs767455<\/jats:italic> and <jats:italic>TNFRSF1B:rs3397<\/jats:italic>. Our SNP haplotype analysis of <jats:italic>TNFRSF1A:rs767455<\/jats:italic> and <jats:italic>TNFRSF1B:rs3397<\/jats:italic> indicates that the G\u2013T haplotype is significantly distributed among patients with CD (46%) and MAP infection susceptibility is also associated with this specific haplotype (31%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The SNPs <jats:italic>TNFRSF1A:rs767455<\/jats:italic> and <jats:italic>TNFRSF1B:rs3397,<\/jats:italic> which are known to affect anti-TNF\u03b1 clinical outcome in CD, were associated with lower corresponding gene expression and higher MAP infection susceptibility.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2018-000246","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T03:35:12Z","timestamp":1549078512000},"page":"e000246","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Genetic polymorphisms in tumour necrosis factor receptors (<i>TNFRSF1A\/1B<\/i>) illustrate differential treatment response to TNF\u03b1 inhibitors in patients with Crohn\u2019s disease"],"prefix":"10.1136","volume":"6","author":[{"given":"Ahmad","family":"Qasem","sequence":"first","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seela","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Digestive and Liver Center of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A","family":"Naser","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"2025073013263728000_6.1.e000246.1","first-page":"264","article-title":"TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis","volume":"1","author":"Victor","year":"2002","journal-title":"J Drugs Dermatol"},{"key":"2025073013263728000_6.1.e000246.2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.1.37"},{"key":"2025073013263728000_6.1.e000246.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.02.001"},{"key":"2025073013263728000_6.1.e000246.4","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.18160"},{"key":"2025073013263728000_6.1.e000246.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"2025073013263728000_6.1.e000246.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"2025073013263728000_6.1.e000246.7","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"6 Suppl 28","key":"2025073013263728000_6.1.e000246.8","first-page":"S152","article-title":"Side effects of anti-TNF therapy: current knowledge","volume":"20","author":"Antoni","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2025073013263728000_6.1.e000246.9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3110"},{"key":"2025073013263728000_6.1.e000246.10","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/S0140-6736(01)06810-6","article-title":"Infliximab-induced aseptic meningitis","volume":"358","author":"Marotte","year":"2001","journal-title":"The Lancet"},{"key":"2025073013263728000_6.1.e000246.11","doi-asserted-by":"publisher","DOI":"10.4065\/76.6.653"},{"key":"2025073013263728000_6.1.e000246.12","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200111000-00009"},{"key":"2025073013263728000_6.1.e000246.13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/14787210.2017.1328276","article-title":"The alternate effects of anti-TNF\u03b1 therapeutics and their role in mycobacterial granulomatous infection in Crohn's disease","volume":"15","author":"Qasem","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025073013263728000_6.1.e000246.14","first-page":"RA27","article-title":"Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease: questioning the hypotheses","volume":"12","author":"Chamberlin","year":"2006","journal-title":"Med Sci Monit"},{"key":"2025073013263728000_6.1.e000246.15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13099-016-0090-8","article-title":"Oxidative stress due to Mycobacterium avium subspecies paratuberculosis (MAP) infection upregulates selenium-dependent GPx activity","volume":"8","author":"Qasem","year":"2016","journal-title":"Gut Pathog"},{"key":"2025073013263728000_6.1.e000246.16","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.3748\/wjg.v24.i25.2764","article-title":"Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-\u03b1 inhibitors (Anti-TNF\u03b1)","volume":"24","author":"Cao","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2025073013263728000_6.1.e000246.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03630.x"},{"key":"2025073013263728000_6.1.e000246.18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humimm.2013.09.017","article-title":"Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab","volume":"75","author":"Medrano","year":"2014","journal-title":"Hum Immunol"},{"key":"2025073013263728000_6.1.e000246.19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/apt.12010","article-title":"Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and\/or acute severe infusion reactions to infliximab in Crohn's disease","volume":"36","author":"Steenholdt","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013263728000_6.1.e000246.20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(04)17058-X","article-title":"Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease","volume":"364","author":"Naser","year":"2004","journal-title":"The Lancet"},{"key":"2025073013263728000_6.1.e000246.21","unstructured":"NCBI , 2018. National Center for Biotechnology Information. Available from: ncbi.nlm.nih.gov"},{"key":"2025073013263728000_6.1.e000246.22","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000158153.71579.b4"},{"key":"2025073013263728000_6.1.e000246.23","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22942"},{"key":"2025073013263728000_6.1.e000246.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068528"},{"key":"2025073013263728000_6.1.e000246.25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318294b2d6"},{"key":"2025073013263728000_6.1.e000246.26","doi-asserted-by":"crossref","first-page":"e100361","DOI":"10.1371\/journal.pone.0100361","article-title":"Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome","volume":"9","author":"Sode","year":"2014","journal-title":"PLoS One"},{"key":"2025073013263728000_6.1.e000246.27","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/701019"},{"key":"2025073013263728000_6.1.e000246.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb03334.x"},{"key":"2025073013263728000_6.1.e000246.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2018-000216","article-title":"TNF\u03b1 inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn's disease to current approved therapy","volume":"5","author":"Qasem","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"key":"2025073013263728000_6.1.e000246.30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.intimp.2015.05.049","article-title":"The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis","volume":"28","author":"Chen","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"2025073013263728000_6.1.e000246.31","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1139\/cjpp-2017-0700","article-title":"Mycobacterial infection influences bone biomarker levels in patients with Crohn's disease","volume":"96","author":"Naser","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"2025073013263728000_6.1.e000246.32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13099-016-0127-z","article-title":"A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn's disease associated with Mycobacterium avium subspecies paratuberculosis","volume":"8","author":"Qasem","year":"2016","journal-title":"Gut Pathog"},{"key":"2025073013263728000_6.1.e000246.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40534.x"},{"key":"2025073013263728000_6.1.e000246.34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363689"},{"key":"2025073013263728000_6.1.e000246.35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2249.1996.tb08292.x","article-title":"Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD)","volume":"103","author":"Bouma","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"2025073013263728000_6.1.e000246.36","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01106-06"},{"key":"2025073013263728000_6.1.e000246.37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/iai.59.5.1823-1831.1991","article-title":"Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic","volume":"59","author":"Crowle","year":"1991","journal-title":"Infect Immun"},{"key":"2025073013263728000_6.1.e000246.38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1128\/iai.52.1.252-262.1986","article-title":"Evidence for inhibition of fusion of lysosomal and prelysosomal compartments with phagosomes in macrophages infected with pathogenic Mycobacterium avium","volume":"52","author":"Frehel","year":"1986","journal-title":"Infect Immun"},{"key":"2025073013263728000_6.1.e000246.39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/jlb.66.5.763","article-title":"Macrophage apoptosis in mycobacterial infections","volume":"66","author":"Fratazzi","year":"1999","journal-title":"J Leukoc Biol"},{"key":"2025073013263728000_6.1.e000246.40","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.4049\/jimmunol.158.9.4320","article-title":"Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages","volume":"158","author":"Fratazzi","year":"1997","journal-title":"J Immunol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2018-000246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:26:44Z","timestamp":1753907204000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2018-000246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2,1]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bmjgast-2018-000246"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2018-000246","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}